Not yet recruitingInterventionalEarly Phase 1Last updated Aug 7, 2026

A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine

Overview

ClinicalTrials.gov ID: NCT07753265
Lead Sponsor: Changchun BCHT Biotechnology Co.INDUSTRY
Brief Summary: Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 13, 2026Estimated
Primary Completion Date: Sep 20, 2026Estimated
Completion Date: Sep 20, 2026Estimated

Study Record Dates

First Submitted: Aug 4, 2026
First Submitted that Met QC Criteria: Aug 4, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 4, 2026
Last Update Posted: Aug 7, 2026Actual
Last Verified: Aug 2026

NCT04334577Completed

Study on Efficacy of Attenuated Zoster Vaccine, Live

NCT06961721Not yet recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

NCT07585370Recruiting

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

NCT02526745Completed

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

NCT07633197Enrolling by invitation

A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)

NCT06801509Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine